Wegovy Tablets Vs Injections

If you have been searching for Wegovy tablets, you are far from alone. Millions of people across the UK are actively looking for an effective, medically approved solution to help them lose weight and improve their long-term health outcomes. The confusion around what form Wegovy actually comes in, what it does, and whether there is a tablet version available is entirely understandable given how rapidly this space has evolved over the past few years. This guide cuts through the noise, addresses the most common questions honestly, and explains exactly what your real options are in 2026.

Quick Summary

Wegovy is a licensed weight loss treatment containing semaglutide, available as a subcutaneous injection in the UK. While a tablet form of semaglutide does exist for type 2 diabetes management, it is not currently licensed for weight loss in the UK. Understanding the difference between what is available and what is approved for your specific goal is essential before starting any treatment.

• Wegovy contains semaglutide 2.4mg and is given as a once-weekly injection, not a tablet
• An oral semaglutide tablet exists (Rybelsus) but is only licensed for type 2 diabetes, not weight loss
• Wegovy is MHRA-approved in the UK for adults with a BMI of 30 or above, or 27 or above with a weight-related health condition
• Clinical trials show users can lose an average of 15% of their body weight over 68 weeks
• Alternative weight loss options, including Mounjaro (tirzepatide), are also available through UK prescribers

Table of Contents

• What Is Wegovy and Does a Tablet Form Exist?
• How Wegovy Works for Weight Loss
• Wegovy Tablets vs Other UK Weight Loss Options
• Who Is Eligible for Wegovy in the UK?
• Side Effects and How to Manage Them
• How to Get Started with Weight Loss Treatment in the UK
• Wegovy vs Other Treatments: Comparison Table
• Key Takeaways
• When to Seek Professional Advice
• Scientific References
• FAQs

What Is Wegovy and Does a Tablet Form Exist?

One of the most common misconceptions that people carry into their search for weight loss medication is that Wegovy tablets are a readily available, swallowable pill. In reality, Wegovy is a brand name for semaglutide 2.4mg, and it is currently only licensed in the UK as a subcutaneous injection administered once weekly using a pre-filled pen device. There is no MHRA-approved tablet version of Wegovy for weight loss in the UK as of 2026.

That said, a related oral medication does exist. Rybelsus is an oral semaglutide tablet manufactured by the same company, Novo Nordisk, and is licensed in the UK for the management of type 2 diabetes. However, Rybelsus contains a lower dose of semaglutide (up to 14mg) and has not been approved for weight management in the UK. Prescribing it off-label for weight loss is not standard practice and would carry significant clinical and regulatory risks.

The pain point here is very real. Many people are needle-averse, and the idea of a weekly injection — even a very fine, short one — can be a genuine barrier to starting treatment. Understanding that the injection pen used for Wegovy is extremely small and relatively painless often helps resolve this concern, and most users report that after the first couple of injections, they become entirely comfortable with the process.

• Wegovy is an injection, not a tablet — this is a common source of confusion
• Rybelsus is an oral semaglutide but is only licensed for type 2 diabetes in the UK
• No oral semaglutide tablet is currently approved in the UK specifically for weight loss
• The Wegovy injection pen is pre-filled, discreet, and designed to minimise discomfort
• Future oral weight loss formulations are in clinical development but have not yet received UK approval

How Wegovy Works for Weight Loss

Understanding the mechanism behind Wegovy tablets and injections helps explain why it is so effective compared to previous generations of weight loss treatment. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists (glucagon-like peptide-1). It works by mimicking a naturally occurring hormone in your body that is released after you eat, signalling to the brain that you are full, slowing down gastric emptying, and reducing your appetite substantially.

The result is that people taking semaglutide simply do not feel as hungry. They feel fuller on less food, experience fewer cravings, and find it far easier to maintain a calorie deficit without the relentless mental battle that most people associate with dieting. This is not willpower — it is pharmacology working with your biology. Clinical data from the STEP 1 trial showed an average weight loss of 14.9% of body weight over 68 weeks in people using Wegovy alongside lifestyle changes.

Beyond appetite suppression, semaglutide also has meaningful effects on cardiovascular risk factors. In 2024, the SELECT trial demonstrated that semaglutide significantly reduced the risk of major cardiovascular events in overweight or obese individuals who did not have diabetes. This has broadened the clinical case for prescribing it in a wider range of patients in 2026 and beyond.

• Semaglutide mimics the GLP-1 hormone to reduce appetite and increase satiety
• It slows gastric emptying, meaning food stays in the stomach longer and hunger is delayed
• Works on the brain's reward centre to reduce food cravings
• Average body weight reduction of nearly 15% seen in large-scale clinical trials
• Additional cardiovascular benefits have been demonstrated in high-risk patients

Wegovy Tablets vs Other UK Weight Loss Options

Because Wegovy tablets in a true oral form are not currently available for weight loss, many people are rightly asking what their alternatives are. The good news is that the UK weight loss treatment landscape in 2026 is broader and more effective than it has ever been. Several clinically proven, MHRA-approved or regulated options exist, and the right one for you will depend on your health history, your BMI, and your personal preferences.

One of the strongest alternatives to Wegovy is Mounjaro weight loss injections (tirzepatide), which is a dual GIP and GLP-1 receptor agonist. Clinical trials have shown tirzepatide to produce even greater average weight loss than semaglutide alone — in some trials, participants lost up to 22.5% of their body weight. It is now widely available through UK online prescribing services and has become a first-choice option for many patients.

For those who are not eligible for prescription-only treatments or who want to support their weight loss journey with over-the-counter options, products such as XLS Medical Weight Loss Plus tablets can complement dietary changes and physical activity. Similarly, Orlos (Orlistat) 60mg weight loss capsules are available without a prescription for eligible adults and work by blocking the absorption of dietary fat.

• Mounjaro (tirzepatide) is a dual-action injectable with potentially greater weight loss than Wegovy
• Saxenda (liraglutide) is an older GLP-1 injectable that requires daily rather than weekly dosing
• Orlistat (Orlos) is an over-the-counter fat blocker suitable for adults with a BMI of 28 or above
• OTC supplements like XLS Medical can support lifestyle-based weight management
• The most appropriate option should always be determined through a clinical assessment

Who Is Eligible for Wegovy in the UK?

Not everyone who wants to lose weight will automatically qualify for Wegovy tablets or injections. MHRA licensing criteria and clinical guidelines set clear eligibility thresholds to ensure the treatment is used appropriately and safely. In the UK, Wegovy is approved for adults who meet at least one of the following criteria when prescribed alongside a reduced-calorie diet and increased physical activity.

To be eligible, you generally need a BMI of 30 kg/m² or higher (classified as obese), or a BMI of 27 kg/m² or higher alongside at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea, or cardiovascular disease. Wegovy is not suitable for people who are pregnant or breastfeeding, those with a personal or family history of medullary thyroid carcinoma, or individuals with multiple endocrine neoplasia syndrome type 2.

It is also worth noting that Wegovy is prescribed as part of a wider weight management programme. It is not a standalone magic solution. Patients are expected to make meaningful dietary and lifestyle changes alongside the medication, and the clinical outcomes are significantly better when this combination approach is followed. A UK prescriber will carry out a full clinical assessment before approving any prescription.

• BMI of 30 or above makes you eligible without any additional conditions
• BMI of 27 to 29.9 is eligible when combined with a weight-related health condition
• Not suitable during pregnancy, breastfeeding, or in those with certain thyroid conditions
• Patients with a history of pancreatitis require careful evaluation before prescribing
• A full online or in-person clinical assessment is required before any prescription is issued

Side Effects and How to Manage Them

Any honest guide to Wegovy tablets and injections must address side effects candidly. The most commonly reported side effects with semaglutide are gastrointestinal in nature, and they are predominantly experienced during the dose escalation phase — the first 16 to 20 weeks of treatment when the dose is being gradually increased from 0.25mg to the full 2.4mg maintenance dose.

Nausea is the most frequently reported side effect, affecting a significant proportion of users, particularly in the first four to eight weeks. This typically improves substantially once the body adjusts to the medication. Other common side effects include vomiting, diarrhoea, constipation, abdominal pain, and reduced appetite. Most of these are mild to moderate in severity and resolve without the need to stop treatment.

There are practical strategies that meaningfully reduce the likelihood and severity of these side effects. Eating smaller meals, avoiding high-fat and spicy foods particularly in the early weeks, staying well hydrated, and not lying down immediately after eating all help. If nausea persists, speaking to your prescriber about temporarily pausing dose escalation is a well-recognised clinical approach. Serious side effects such as pancreatitis, gallbladder disease, or severe allergic reactions are rare but require immediate medical attention.

• Nausea, vomiting, and diarrhoea are the most common side effects and usually improve over time
• Eating slowly and in smaller portions helps manage nausea during the early treatment period
• Staying hydrated is essential, particularly if experiencing vomiting or diarrhoea
• Dose escalation can be slowed if side effects are significant — always discuss with your prescriber
• Seek urgent medical advice if you experience severe abdominal pain, jaundice, or signs of an allergic reaction

How to Get Started with Weight Loss Treatment in the UK

One of the biggest pain points for people seeking Wegovy tablets or injections is simply knowing where to start. The NHS pathway for weight management can be slow, and NHS prescribing of Wegovy has been limited by national guidance and supply pressures. As a result, many people are turning to regulated private online prescribing services, which have made access faster, more convenient, and more straightforward than ever in 2026.

The process typically involves completing an online medical questionnaire that covers your health history, current medications, BMI, and weight-related health conditions. A UK-registered prescriber then reviews your answers and, if appropriate, issues a private prescription. The medication is dispensed by a registered pharmacy and delivered to your address in discreet packaging. The entire process from assessment to delivery can often be completed within a few days.

When selecting a service, always ensure you are using a provider registered with the Care Quality Commission (CQC) and that prescriptions are issued by GPhC-registered pharmacists or GMC-registered doctors. Look for services that include ongoing clinical monitoring, not just a one-time assessment. XLS Medical Direct Fat Binder sachets are also available for those looking for OTC support to complement a weight management programme while awaiting prescription access.

• NHS access to Wegovy is limited — private prescribing services offer a regulated, accessible alternative
• Complete an online clinical assessment with a UK-registered prescriber before any prescription is issued
• Ensure the provider is CQC-registered and that prescribers are GMC or GPhC-registered
• Ongoing monitoring should be included, not just a one-off assessment
• Discreet delivery is standard practice with reputable UK online pharmacy services

Wegovy vs Other UK Weight Loss Treatments: Comparison Table

Treatment	Active Ingredient	Form	Average Weight Loss	Frequency	Prescription Required
Wegovy	Semaglutide 2.4mg	Subcutaneous injection	~15% body weight	Once weekly	Yes
Mounjaro	Tirzepatide	Subcutaneous injection	Up to 22.5% body weight	Once weekly	Yes
Saxenda	Liraglutide 3mg	Subcutaneous injection	~8% body weight	Once daily	Yes
Orlos (Orlistat)	Orlistat 60mg	Oral capsule	~5–7% body weight	Three times daily with meals	No (OTC)
XLS Medical Weight Loss Plus	Cactinea, Phaseolus vulgaris extract	Tablet	Supports dietary management	As directed	No (OTC)
Rybelsus (oral semaglutide)	Semaglutide 3–14mg	Oral tablet	Not licensed for weight loss in UK	Once daily	Yes (diabetes only)

Key Takeaways

• There is currently no licensed version of Wegovy tablets for weight loss in the UK — the approved form is a once-weekly subcutaneous injection
• Oral semaglutide (Rybelsus) exists but is only approved in the UK for type 2 diabetes, not for weight management
• Wegovy is clinically proven to produce an average weight loss of around 15% of body weight when combined with lifestyle changes
• Alternatives such as Mounjaro (tirzepatide) and Orlistat offer different profiles and may be more appropriate depending on your clinical picture
• UK-regulated online prescribing services make it possible to access evidence-based weight loss treatment quickly, safely, and discreetly

When to Seek Professional Advice

Weight loss treatment is a medical matter and should always involve qualified clinical oversight. You should speak to a prescriber or your GP promptly if you experience severe or persistent nausea, vomiting, or abdominal pain during treatment, as these can occasionally indicate a more serious condition such as pancreatitis. If you notice signs of a severe allergic reaction — including swelling of the face or throat, difficulty breathing, or a rapid heartbeat — stop taking the medication immediately and seek emergency medical care.

You should also seek professional advice before starting any weight loss treatment if you have a history of eating disorders, thyroid cancer, kidney disease, gallbladder disease, or are taking insulin or other diabetes medications. A full medication review is essential to identify potential interactions. If you are unsure whether you are eligible or which treatment is right for you, completing a structured online clinical assessment with a registered UK prescriber is the safest and most efficient first step.

Scientific References

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021. (STEP 1 Trial)
2. National Institute for Health and Care Excellence (NICE). "Semaglutide for managing overweight and obesity." Technology Appraisal Guidance TA875, 2023.
3. Medicines and Healthcare products Regulatory Agency (MHRA). Product information and licensing updates for semaglutide 2.4mg (Wegovy). UK Government, 2023–2026.

Frequently Asked Questions

How long does it take to see results with Wegovy?

Results with Wegovy typically begin within the first four to eight weeks of treatment, with most clinical trials showing meaningful weight reduction by week twelve. The full benefit of Wegovy is usually seen over 68 weeks of continued use alongside a reduced-calorie diet and increased physical activity.

Is Wegovy safe for long-term use in the UK?

Wegovy is considered safe for long-term use when prescribed and monitored by a qualified healthcare professional. It is licensed by the MHRA and approved for use in adults with obesity or overweight with a weight-related health condition. Regular clinical reviews are recommended throughout treatment.

Can you take Wegovy with other weight loss medications?

Wegovy should not be combined with other GLP-1 receptor agonists or insulin without direct medical supervision. It may be used alongside certain lifestyle support supplements, but combining it with prescription weight loss medications such as Orlistat or Tirzepatide requires a prescriber's assessment to ensure safety.

What is the dose of Wegovy for weight loss?

The dose of Wegovy for weight loss starts at 0.25mg once weekly and is gradually increased over 16 to 20 weeks to the full maintenance dose of 2.4mg once weekly. This slow dose escalation is designed to reduce the likelihood of gastrointestinal side effects such as nausea.